drugset / Trial / NCT02397473

A Study Of Galcanezumab In Participants With Episodic Cluster Headache

NCT02397473

Phase 3 Completed 109 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headaches.

Timeline

Start
2015-05-22
Primary completion
2018-02-12
Completion
2018-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Galcanezumab Monoclonal antibody 300 mg Subcutaneous